#97 Fibrates: Statin’s Trusty Sidekick or Lackluster Fallback?
CLINICAL QUESTION
Do fibrates reduce cardiovascular (CV) events?
BOTTOM LINE
When used alone, fibrates reduce non-fatal coronary events, but have no effect on mortality or other CV events, including stroke. Current evidence suggests fibrates provide no advantage when added to statin therapy.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
At least ten systematic reviews evaluate fibrates on CV disease with similar findings.1-10 Focusing on the most up-to-date and complete:
- Meta-analysis1 of 18 trials (45,058 patients) of fibrates versus placebo over one to six years:
- 10% (confidence interval 0-18%) relative risk reduction (RRR) in CV events.
- Primarily due to a 19% RRR in non-fatal coronary events.
- No significant effect on all-cause mortality, vascular mortality or stroke.
- Coronary benefits seen in both primary and secondary prevention trials.
- 10% (confidence interval 0-18%) relative risk reduction (RRR) in CV events.
- Only one trial (ACCORD11) evaluated a fibrate or placebo added to statin therapy:
- No statistically significant difference in cardiovascular events over 4.7 years.
- Fenofibrate 10.5%, placebo 11.3% (p=0.32).
- No statistically significant difference in cardiovascular events over 4.7 years.
- The latest Canadian dyslipidemia guidelines12 recommend against routine use of fibrates in patients taking statins.
- Before initiating a fibrate, consider optimizing other CV interventions that provide a better value, for example:
- In a primary prevention patient with 10% risk of CV disease over 10 years:
- Fibrates reduce CV risk to 9%;1
- Statins reduce CV risk to 7.5%;13
- Thiazides reduce CV risk to 7%.14
- Whereas fibrate benefits are limited to non-fatal coronary events, statins and thiazides also reduce stroke and mortality risk.
- In a primary prevention patient with 10% risk of CV disease over 10 years:
- Theoretically fibrates could reduce the risk of pancreatitis (by reducing triglycerides). The best evidence15 suggests they do the opposite:
- Fibrates increase pancreatitis (Number Needed to Harm (NNH)=935) at five years.
- Statins reduce pancreatitis (Number Needed to Treat (NNT)=1200) at five years.
- Additional potential adverse effects associated with fibrates include:
- Venous thromboembolism (NNH ~110)16 over five years;
- Acute kidney injury (NNH ~450)17 during first three months of initiation;
- Rhabdomyolysis over five years for fibrates (NNH ~5050) and for fibrates with statins (NNH ~1975).18
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
